- Home
- SNBR vs CLLS Comparison
SNBR vs CLLS Comparison
Compare SNBR & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNBR
- CLLS
- Stock Information
- Founded
- SNBR 1987
- CLLS 1999
- Country
- SNBR United States
- CLLS France
- Employees
- SNBR N/A
- CLLS N/A
- Industry
- SNBR Home Furnishings
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- SNBR Consumer Discretionary
- CLLS Health Care
- Exchange
- SNBR Nasdaq
- CLLS Nasdaq
- Market Cap
- SNBR 154.1M
- CLLS 143.4M
- IPO Year
- SNBR 1998
- CLLS 2007
- Fundamental
- Price
- SNBR $8.28
- CLLS $2.52
- Analyst Decision
- SNBR Hold
- CLLS Buy
- Analyst Count
- SNBR 2
- CLLS 1
- Target Price
- SNBR $9.00
- CLLS $4.00
- AVG Volume (30 Days)
- SNBR 603.3K
- CLLS 227.4K
- Earning Date
- SNBR 07-30-2025
- CLLS 08-05-2025
- Dividend Yield
- SNBR N/A
- CLLS N/A
- EPS Growth
- SNBR N/A
- CLLS N/A
- EPS
- SNBR N/A
- CLLS N/A
- Revenue
- SNBR $1,605,108,000.00
- CLLS $54,747,000.00
- Revenue This Year
- SNBR N/A
- CLLS $48.52
- Revenue Next Year
- SNBR $4.27
- CLLS $5.17
- P/E Ratio
- SNBR N/A
- CLLS N/A
- Revenue Growth
- SNBR N/A
- CLLS 351.26
- 52 Week Low
- SNBR $4.48
- CLLS $1.10
- 52 Week High
- SNBR $20.75
- CLLS $2.66
- Technical
- Relative Strength Index (RSI)
- SNBR 55.18
- CLLS 69.04
- Support Level
- SNBR $6.45
- CLLS $2.00
- Resistance Level
- SNBR $9.41
- CLLS $2.36
- Average True Range (ATR)
- SNBR 0.73
- CLLS 0.21
- MACD
- SNBR 0.17
- CLLS 0.05
- Stochastic Oscillator
- SNBR 61.82
- CLLS 87.21
About SNBR Sleep Number Corporation
Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.